文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

阿根廷COVID-19有创通气患者的临床特征与结局(SATICOVID):一项前瞻性多中心队列研究

Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study.
PubMed 文献 · Lancet Respir Med · 2021-07-02
一句话结论阿根廷63个ICU的前瞻性队列显示,有创通气的COVID-19患者院内死亡率为57.7%,年龄、Charlson评分、ICU外插管、第1天使用血管升压药、D-二聚体、PaO2/FiO2、动脉pH、驱动压、急性肾损伤和入院月份为独立预测因素。

该研究在阿根廷63个ICU前瞻性纳入1909例RT-PCR确诊COVID-19且有创机械通气的成人患者,主要终点为全因院内死亡。院内死亡率为57.7%(1101/1909),ICU死亡率为57.0%(1088/1909),87.6%发生ARDS,61.6%接受俯卧位通气,中位通气时间13天。Cox回归识别出年龄、Charlson评分、ICU外插管、第1天使用血管升压药、D-二聚体、PaO2/FiO2、动脉pH、驱动压、急性肾损伤和入院月份为独立预测因素。作者认为肺保护性通气使用广泛但死亡率高,预测因素与高收入国家研究大致一致。

要点

  • 在阿根廷63个ICU的1909例有创通气COVID-19患者中,院内死亡率为57.7%(1101/1909),ICU死亡率为57.0%(1088/1909)。
  • 第1天中位潮气量为6.1 mL/kg预测体重(IQR 6.0-7.0),PEEP为10 cm H2O(8-12),驱动压为12 cm H2O(10-14),PaO2/FiO2为160(IQR 111-218)。
  • 87.6%的患者发生急性呼吸窘迫综合征,61.6%接受俯卧位通气,中位有创通气时间为13天(IQR 7-22)。
  • Cox回归显示ICU外插管(HR 1.37,95%CI 1.10-1.71)、第1天使用血管升压药(HR 1.29,95%CI 1.07-1.55)、急性肾损伤(HR 1.66,95%CI 1.36-2.03)和第1天驱动压(HR 1.05,95%CI 1.03-1.08)与死亡独立相关。
  • 死亡患者中43.8%(462例)死于难治性低氧血症,常与脓毒性休克重叠(n=174)。

适用人群与场景

  • 年龄≥18岁、RT-PCR确诊COVID-19、接受有创机械通气并入住阿根廷63个ICU的患者。
  • 研究期间为2020年3月20日至2020年10月31日。

研究设计与关键结果

  • 研究类型为前瞻性、多中心队列研究(SATICOVID),纳入1909例有创通气COVID-19患者,来自阿根廷63个ICU,中位年龄62岁(IQR 52-70),67.8%为男性。
  • 主要终点全因院内死亡率为57.7%(1101/1909),ICU死亡率为57.0%(1088/1909);中位有创通气时间13天(IQR 7-22)。
  • 第1天呼吸生理指标:潮气量6.1 mL/kg预测体重(IQR 6.0-7.0),PEEP 10 cm H2O(8-12),PaO2/FiO2 160(IQR 111-218),呼吸系统顺应性36 mL/cm H2O(29-44),驱动压12 cm H2O(10-14),FiO2 0.60(0.45-0.80);潮气量至第7天显著增加,PEEP至第7天轻微但显著下降。
  • 87.6%(1672/1909)发生急性呼吸窘迫综合征,61.6%(1176/1909)接受俯卧位通气,49.2%(939/1909)第1天需要血管升压药。
  • 死亡患者中43.8%(462例)死于难治性低氧血症,常与脓毒性休克重叠(n=174)。
  • Cox回归独立预测因素:年龄(HR 1.02,95%CI 1.01-1.03)、Charlson评分(HR 1.16,95%CI 1.11-1.23)、ICU外插管(HR 1.37,95%CI 1.10-1.71)、第1天使用血管升压药(HR 1.29,95%CI 1.07-1.55)、D-二聚体(HR 1.02,95%CI 1.01-1.03)、第1天PaO2/FiO2(HR 0.998,95%CI 0.997-0.999)、第1天动脉pH(HR 1.01,95%CI 1.00-1.01)、第1天驱动压(HR 1.05,95%CI 1.03-1.08)、急性肾损伤(HR 1.66,95%CI 1.36-2.03)、入院月份(HR 1.10,95%CI 1.03-1.18)。

证据类型、等级与局限

  • 证据类型:前瞻性、多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,肺保护性通气在阿根廷有创通气COVID-19患者中广泛使用,但死亡率仍高;预测因素与高收入国家研究大致一致。
  • 作者认为,COVID-19对稀缺医护人员的持续负担可能促成了研究期间阿根廷的高死亡率。
  • 作者认为,这些数据可能有助于识别中等收入国家及其他地区患者管理的改进点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although COVID-19 has greatly affected many low-income and middle-income countries, detailed information about patients admitted to the intensive care unit (ICU) is still scarce. Our aim was to examine ventilation characteristics and outcomes in invasively ventilated patients with COVID-19 in Argentina, an upper middle-income country.

METHODS: In this prospective, multicentre cohort study (SATICOVID), we enrolled patients aged 18 years or older with RT-PCR-confirmed COVID-19 who were on invasive mechanical ventilation and admitted to one of 63 ICUs in Argentina. Patient demographics and clinical, laboratory, and general management variables were collected on day 1 (ICU admission); physiological respiratory and ventilation variables were collected on days 1, 3, and 7. The primary outcome was all-cause in-hospital mortality. All patients were followed until death in hospital or hospital discharge, whichever occurred first. Secondary outcomes were ICU mortality, identification of independent predictors of mortality, duration of invasive mechanical ventilation, and patterns of change in physiological respiratory and mechanical ventilation variables. The study is registered with ClinicalTrials.gov, NCT04611269, and is complete.

FINDINGS: Between March 20, 2020, and Oct 31, 2020, we enrolled 1909 invasively ventilated patients with COVID-19, with a median age of 62 years [IQR 52-70]. 1294 (67·8%) were men, hypertension and obesity were the main comorbidities, and 939 (49·2%) patients required vasopressors. Lung-protective ventilation was widely used and median duration of ventilation was 13 days (IQR 7-22). Median tidal volume was 6·1 mL/kg predicted bodyweight (IQR 6·0-7·0) on day 1, and the value increased significantly up to day 7; positive end-expiratory pressure was 10 cm H2O (8-12) on day 1, with a slight but significant decrease to day 7. Ratio of partial pressure of arterial oxygen (PaO2) to fractional inspired oxygen (FiO2) was 160 (IQR 111-218), respiratory system compliance 36 mL/cm H2O (29-44), driving pressure 12 cm H2O (10-14), and FiO2 0·60 (0·45-0·80) on day 1. Acute respiratory distress syndrome developed in 1672 (87·6%) of patients; 1176 (61·6%) received prone positioning. In-hospital mortality was 57·7% (1101/1909 patients) and ICU mortality was 57·0% (1088/1909 patients); 462 (43·8%) patients died of refractory hypoxaemia, frequently overlapping with septic shock (n=174). Cox regression identified age (hazard ratio 1·02 [95% CI 1·01-1·03]), Charlson score (1·16 [1·11-1·23]), endotracheal intubation outside of the ICU (ie, before ICU admission; 1·37 [1·10-1·71]), vasopressor use on day 1 (1·29 [1·07-1·55]), D-dimer concentration (1·02 [1·01-1·03]), PaO2/FiO2 on day 1 (0·998 [0·997-0·999]), arterial pH on day 1 (1·01 [1·00-1·01]), driving pressure on day 1 (1·05 [1·03-1·08]), acute kidney injury (1·66 [1·36-2·03]), and month of admission (1·10 [1·03-1·18]) as independent predictors of mortality.

INTERPRETATION: In patients with COVID-19 who required invasive mechanical ventilation, lung-protective ventilation was widely used but mortality was high. Predictors of mortality in our study broadly agreed with those identified in studies of invasively ventilated patients in high-income countries. The sustained burden of COVID-19 on scarce health-care personnel might have contributed to high mortality over the course of our study in Argentina. These data might help to identify points for improvement in the management of patients in middle-income countries and elsewhere.

TRANSLATION: For the Spanish translation of the Summary see Supplementary Materials section.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Estenssoro E, Loudet CI, Ríos FG, et al. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study. Lancet Respir Med. 2021. PMID: 34224674. doi:10.1016/S2213-2600(21)00229-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。